June 10th 2017, 9:04pm
Alan Blassberg, Director/Producer of Pink and Blue: Colors of Hereditary Cancer, discusses being a male BRCA carrier.
June 10th 2017, 8:09pm
Sharon Bober, PhD, discusses how patients can ask their doctors about sexual health.
June 10th 2017, 5:56pm
Those considering mastectomy to help prevent inherited breast cancer, or because they’ve been diagnosed with the disease, are likely to find themselves sorting through a host of complex questions.
June 10th 2017, 4:22pm
For women genetically predisposed to ovarian cancer, prevention is extremely important. But what are the most effective and least invasive prevention techniques, and when is the best time in life to employ them?
June 9th 2017, 11:58pm
Knowing that you have an inherited gene mutation can allow you and your family members to look into prevention or detect a cancer at an early stage.
June 9th 2017, 11:15pm
Angela Fishbaugh, author of "Angela's Decision," discusses how to discover your skills and story within.
June 9th 2017, 11:02pm
“This is the first phase 3 study to show an advantage of a PARP inhibitor over standard of care chemotherapy in breast cancer patients with a BRCA mutation,” said principal OLYMPIAD investigator Mark E. Robson, M.D., Clinic Director of the Clinical Genetics Service at Memorial Sloan Kettering Cancer Center.
June 9th 2017, 10:32pm
Ilana Cass, M.D. of Cedars-Sinai Medical Center discusses some of the unknown potential side effects of preventive surgery for ovarian cancer.
June 9th 2017, 8:48pm
Sue Friedman, executive director and founder of FORCE, is a hereditary breast cancer survivor herself and has been concentrating on being the support system for others that she didn’t have when she was going through her battle 20 years ago.
June 9th 2017, 8:03pm
The program XRAYS is a resource to help patients, survivors and their loved ones make sense of the articles on hereditary cancer they see in the mainstream media and via social media platforms.
June 9th 2017, 5:21pm
While genetic testing for cancer has some obvious benefits, it also creates ethical dilemmas in many cases.
June 8th 2017, 6:28pm
PolyBalm was effective in mitigating chemotherapy-related nail damage, according to a recent study presented at ASCO.
June 7th 2017, 5:44pm
Bavencio and Inlyta together produced a promising response for some patients with renal cell carcinoma.
June 6th 2017, 10:06pm
When combined with the IDO1 inhibitor epacadostat, Keytruda (pembrolizumab), a PD-1 inhibitor, resulted in an overall response rate (ORR) of 35 percent in patients with advanced urothelial carcinoma, according to results from the phase 1/2 ECHO-202/KEYNOTE-037 trial.
June 6th 2017, 5:59pm
Many patients with relapsed or refractory multiple myeloma saw clinical remission with CAR T-cell therapy.
June 5th 2017, 9:55pm
Keytruda (pembrolizumab) showed promising signs of clinical activity for patients with advanced gastric or gastroesophageal junction (GEJ), according to updated findings from KEYNOTE-059 study that were presented at the 2017 American Society for Clinical Oncology (ASCO) Annual Meeting.
June 5th 2017, 6:48pm
Promising results from a new agent may set the stage for a new standard of care for patients with TRK fusion mutations.
June 4th 2017, 10:21pm
An online tool helped patients to report their symptoms in real time, improving survival, according to findings presented at ASCO 2017.
June 4th 2017, 10:06pm
According to findings presented at ASCO 2017, patients with low-risk advanced colon cancer would benefit from reducing the length of chemotherapy after surgery.
June 4th 2017, 8:19pm
The psychotherapty known as CALM has been shown to ease depression and distress in patients with advanced cancer.
June 4th 2017, 5:59pm
According to phase III findings presented at ASCO 2017, single radiation treatment relieved the symptoms of spinal cord compression in patients with advanced cancer as effectively as a five-day course.
June 3rd 2017, 8:38pm
There are fewer reported incidences of severe long-term side effects after childhood cancer treatment, according to a recent study.
June 2nd 2017, 11:47pm
A recent clinical trial showed that psychological intervention can ease patients' anxiety and fear of recurrence.
June 2nd 2017, 11:07pm
Progression-free survival was improved for postmenopausal women with HER2-negative advanced breast cancer when treated with Kisqali plus letrozole.
March 15th 2017, 9:19pm
SGO Annual Meeting on Women's Cancer
Patients with BRCA-mutant ovarian cancer saw an improved progression-free survival with Lynparza, according to a recent study.
March 15th 2017, 8:20pm
SGO Annual Meeting on Women's Cancer
Improved overall survival (OS) was achieved in patients with BRCA-proficient ovarian cancer who were treated with a carboplatin desensitization regimen.
March 15th 2017, 6:41pm
SGO Annual Meeting on Women's Cancer
Jubilee Brown, M.D., obstetrician-gynecologist, Levine Cancer Institute, Carolinas HealthCare System, discusses genetic counseling for patients with breast and ovarian cancer.
March 15th 2017, 4:52pm
SGO Annual Meeting on Women's Cancer
PARP inhibitors like niraparib are bringing big change to the treatment of ovarian cancer, says Kathleen N. Moore, M.D.
March 15th 2017, 12:37am
SGO Annual Meeting on Women's Cancer
Kathleen N. Moore, M.D., assistant professor, Stephenson Cancer Center, The University of Oklahoma, discusses developing new PARP inhibitors for patients with ovarian cancer. These new drugs may meaningfully prolong survival from a couple months to potentially years.
March 14th 2017, 10:32pm
SGO Annual Meeting on Women's Cancer
The PARP inhibitor niraparib proved to be effective in improving progression-free survival in recurrent ovarian cancer, according to a recent study.